Metformin use reduced the risk of stomach cancer in diabetic patients in Korea: an analysis of Korean NHIS-HEALS database
- 27 May 2020
- journal article
- research article
- Published by Springer Nature in Gastric Cancer
- Vol. 23 (6) , 1075-1083
Abstract
Background Diabetes mellitus (DM) increases atherosclerotic cardiovascular complications and cancer risks. Stomach cancer is the most common cancer in Korea. Although the survival rate of stomach cancer has improved, the disease burden is still high. Methods This retrospective study investigated the association between metformin use and stomach cancer incidence in a Korean population using the National Health Insurance Service-National Health Screening Cohort database. Participants aged 40–80 years old at the baseline period (2002–2003) were enrolled. The study population was categorized into three groups of metformin non-users with DM, metformin users with DM, and individuals without DM (No DM group). Results A total of 347,895 participants (14,922 metformin non-users, 9891 metformin users, and 323,082 individuals without DM) were included in the final analysis. The median follow-up duration was 12.70 years. The estimated cumulative incidence of stomach cancer was highest in metformin non-users and lowest in the No DM group (men vs. women: 3.75 vs. 1.97% in metformin non-users, 2.91 vs. 1.53% in metformin users, and 2.54 vs. 0.95% in the No DM group). Compared with metformin non-users, the hazard ratios (95% confidence intervals) for stomach cancer incidence of metformin users and the No DM group were 0.710 (0.579–0.870) and 0.879 (0.767–1.006) in men and 0.700 (0.499–0.981) and 0.701 (0.544–0.903) in women, respectively, after full adjustment. Conclusions Metformin users with DM in the Korean population were at lower risk of stomach cancer incidence after controlling for potential confounding factors.Keywords
Funding Information
- Ministry of Health and Welfare (HI19C0526)
- Korea Science and Engineering Foundation (2017R1C1B5015192)
This publication has 21 references indexed in Scilit:
- Effects of metformin and other biguanides on oxidative phosphorylation in mitochondriaBiochemical Journal, 2014
- Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenaseNature, 2014
- Long‐term metformin use reduces gastric cancer risk in type 2 diabetics without insulin treatment: a nationwide cohort studyAlimentary Pharmacology & Therapeutics, 2014
- Metformin—mode of action and clinical implications for diabetes and cancerNature Reviews Endocrinology, 2014
- AMP-Activated Protein Kinase: A Target for Drugs both Ancient and ModernChemistry & Biology, 2012
- Lower Risk of Cancer in Patients on Metformin in Comparison With Those on Sulfonylurea DerivativesDiabetes Care, 2011
- Cellular and molecular mechanisms of metformin: an overviewClinical Science, 2011
- Type 2 diabetes increases and metformin reduces total, colorectal, liver and pancreatic cancer incidences in Taiwanese: a representative population prospective cohort study of 800,000 individualsBMC Cancer, 2011
- Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chainBiochemical Journal, 2000
- Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)The Lancet, 1998